ARTICLE | Company News
JV to combine technologies into one gene and cell therapy manufacturing platform
Bio-Techne, Fresenius Kabi and Wilson Wolf will create a platform to scale up manufacturing as Bellicum sells off facility to save costs
January 22, 2020 1:27 AM UTC
Updated on Jan 22, 2020 at 1:32 AM UTC
Two manufacturing deals Tuesday underscore manufacturing's vital role in the development of next-generation gene and cell therapies. The first, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf, will combine the partners' scalable technologies and processes into one manufacturing platform to develop and commercialize cell and gene therapies.
Bio-Techne Corp. (NASDAQ:TECH) will use its proteins, reagents, media and gene-editing technologies to activate, reprogram and stimulate cell growth...